A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Atopaxar (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Biomarker
  • Acronyms LANCELOT-ACS
  • Sponsors Eisai Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Sep 2014 According to European Clinical Trials Database, the trial status is ongoing in France.
    • 23 Oct 2012 Planned number of patients changed from 600 to 720 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top